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Abstract 
 Little information is available concerning whether incorporation of dietary 
omega-3 fatty acids into plasma lipids changes during healthy aging. Elderly (74 ± 4 y 
old) and young (24 ± 2 y old) adults were given a fish oil supplement for 3 wk that 
provided 680 mg/d of docosahexaenoic acid and 320 mg/d of eicosapentaenoic acid, 
followed by a 2 wk wash-out period. Compliance was monitored by spiking the 
capsules with carbon-13 glucose, the excretion of which was measured in breath 
CO2. In response to the supplement, plasma docosahexaenoic acid rose 42% more 
in the elderly but eicosapentaenoic responded similarly in both groups. Despite 
raising docosahexaenoic acid intake by 5-10 fold, the supplement did not raise 
plasma free docosahexaenoic acid (% or mg/dl) in either group. We conclude that 
healthy aging is accompanied by subtle but significant changes in DHA incorporation 
into plasma lipids.   
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INTRODUCTION 
 Studies using both epidemiological (1,2) and other approaches (3) are broadly 
supportive of a protective role of fish 3 fatty acids against Alzheimer’s disease, the 
most common form of declining cognition in the elderly. We sought to address one 
background question that has received little attention but which may have an impact 
on why the elderly may be vulnerable to cognitive decline: is healthy aging 
associated with physiological (obligatory) changes in metabolism in 3 fatty acid 
metabolism? More specifically, we asked - do plasma 3 fatty acid levels respond 
similarly to a fish oil supplement in healthy young and elderly subjects? Given the 
vulnerability of the elderly to cognitive decline and the role of docosahexaenoic acid 
(22:63; DHA) in cognitive function, we hypothesized that aging would dampen the 
plasma DHA response to an 3 fatty supplement.  
In order to be sure of a possible age-related difference in 3 metabolism, 
compliance had to be verified independently of reported capsule counts or changes 
in plasma 3 fatty acids. Since our young and elderly participants were free-living, 
we could not readily supervise in person the consumption of the 3 fatty acid 
supplement, so a new method of assessing compliance was developed and validated 
prior to doing the metabolic assessment.  
The data reported here focus on plasma values for the two principal 3 fatty 
acids in the supplement provided - eicosapentaenoic acid (20:53; EPA) and DHA, 
as well as the principal ’competing’ 6 fatty acid - arachidonic acid (20:46; ARA) 
(4). Because the level of ‘free’ (non-esterified) plasma DHA and ARA is thought to be 
important for their uptake by the brain (5), those data are provided as both 
percentages and concentrations.  
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METHODS 
 All procedures reported here were approved by the Human Ethics Research 
Committee of the Health and Social Sciences Center – Sherbrooke University 
Geriatrics Institute, which is the committee mandated to oversee human 
experimentation at our institution. 
Compliance Methodology: In addition to capsule counts and a checklist completed by 
the subjects, we independently verified compliance by adding a small amount of 
carbon-13-labeled glucose (13C; Cambridge Isotopes Limited, Andover, USA) to the 
3 fatty acid capsules used in the metabolic study. This was done only during the 
third week of the study. With 10 mg/capsule of 13C-glucose, we established in 
preliminary tests that if breath 13C value during the supplementation period did not 
exceed 2.5 times the baseline 13C value, the subject was non-compliant on that day. 
Non-compliance on more than one day/week led to exclusion of the subject’s data 
from the final analysis.  
3 Fatty Acid Supplementation: Following informed written consent, the participants’ 
medical histories were taken by a registered nurse and 12 h fasting blood chemistries 
were assessed. Inclusion criteria were: 18-29 y old or 70-79 y old, thyroid stimulating 
hormone (0.35-7.0 mIU/L), glucose (3.3-6.1 mmol/L), cholesterol (3.3-4.6 mmol/L in 
the young and 3.3-6.2 mmol/L in the elderly), triglycerides (0.6-2.3 mmol/L), and 
hemoglobin A1c (4.0-6.0 mmol/L). Exclusion criteria were: smokers, 
pregnancy/lactation, <18 y old or between 30-70 y old or >70 y old, or use of 
medication for diabetes, liver disease, renal disease, hypertension, anemia or low 
serum albumin or other evidence of malnutrition. An upper limit of 3.0% DHA in 
plasma total lipids was set to exclude those individuals who were probably already 
consuming 3 fatty acid supplements or relatively high amounts of fish.  
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 A dose of 3 fatty acids (EPA and DHA) was provided that was calculated to 
be 4-5 times the average intake in Quebec of 3 fatty acids from fish or seafood (6). 
One lot of an encapsulated commercially available brand of fish oil was purchased in 
sufficient quantity to supply all the participants for the duration of the study (Genuine 
Health, O3mega+ Think, Toronto, Canada). According to our measurements, two 
capsules/d provided 1070 mg of 3 fatty acids: 3 mg -linolenic acid (18:33), 64 mg 
docosapentaenoic acid (22:53), 323 mg of eicosapentaenoic acid (20:53; EPA) 
and 680 mg of DHA (Table 1). Participants consumed the two capsules each morning 
for 3 wk, followed by a 2 wk wash-out during which no capsules were consumed. 
Participants were told to take the capsules in the morning at breakfast and to take 
duplicate breath samples not less than 2 and not more than 4 h later. Fasting blood 
samples were collected once weekly between 7-8 a.m. They were anti-coagulated in 
EDTA and the plasma removed by centrifugation and stored at -20o C.  
Analytical Methodology: For fatty acid analysis, total lipids from 0.5 ml were extracted 
into chloroform-methanol, internal standards added, the lipid classes separated by 
neutral lipid thin layer chromatography, and fatty acid methyl; esters prepared and 
analyzed as previously described (7). Glucose, triglycerides, total cholesterol, and 
free fatty acids were measured by an automated analyzer (Xpand, Dade-Behring, 
Mississauga, ON). 
Statistics: Using DHA values in plasma total lipids analyzed in our laboratory as a 
benchmark, power analysis showed that 9-10 subjects/group would be sufficient to 
demonstrate a significant effect of the supplement. Data are shown as mean±SD. 
Fatty acid values were not normally distributed so the non-parametric Mann-Whitney 
test was used (SPSS; Chicago, Illinois, USA) with the cut-off for statistical 
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significance set at p<0.05. Freidman’s test was used to verify whether the young and 
elderly groups differed when there was no effect of the supplement. 
 
RESULTS 
Compliance: Based on the rise in 13C in breath CO2 from the 13C-glucose on the 
capsules, we observed that one young participant was non-compliant on two 
occasions and another was non-compliant on six of the seven days tested, leaving 
n=9 in the young group. Lack of change in plasma 3 fatty acids in the least 
compliant participant supported the 13C compliance data. All 10 elderly participants 
who started the supplementation study were included in the final analyses.  
3 Fatty Acid Supplementation: DHA in plasma total lipids was not different between 
the two groups at baseline. After 3 wk supplementation, in the elderly, plasma DHA 
stabilized 46% higher than baseline (p<0.05), a rise that was 42% higher than in the 
young group. During the wash-out, plasma DHA declined to a similar value in both 
groups (Figure 1). After the supplementation, EPA in plasma total lipids rose similarly 
in both groups. In both groups, whereas % DHA rose in plasma phospholipids during 
the supplementation period, EPA was largely unaffected in phospholipids, and 
neither changed significantly in plasma triglycerides (data not shown). Other 3 fatty 
acids (-linolenic acid, 3 docosapentaenoic acid) remained statistically unchanged 
during supplementation and did not differ between the two groups.  
Expressed as a % of the plasma free (non-esterified) fatty acid pool, free DHA 
did not differ between the two groups and also did not change significantly during 
either the supplementation or the wash-out phase of the study. The plasma 
concentration of free DHA also did not change during fish oil supplementation, but 
owing to the higher concentration of plasma total free fatty acids in the elderly, the 
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plasma concentration of free DHA averaged over both phases of the study was 82% 
higher in the elderly (data not shown). EPA was largely undetectable in plasma free 
fatty acids so the few values that were recorded could not be compiled and are not 
reported here. 
In the elderly, plasma total ARA started and remained about 20% higher 
throughout the supplementation and wash-out periods (p<0.00004; Figure 1).  
The higher % of ARA in plasma of the elderly seen both at baseline and throughout 
the study was a function of higher ARA in both phospholipids and triglycerides but 
not free fatty acids (data not shown). When expressed as a % of the total free fatty 
acid pool, free ARA did not differ between the two groups at any time point. When 
expressed as a concentration (mg/dL), free ARA differed between the two groups at 
a couple of time points but not overall (data not shown). 
There was no treatment effect on the plasma concentration of the main 
plasma lipid classes during the supplementation period or during the wash-out. 
Hence, during the overall study period, the elderly averaged 9% higher 
phospholipids, 19% higher triglycerides, and 64% higher free fatty acids; all p<0.05). 
The significant difference in plasma total cholesterol between the two groups seen at 
baseline was unaffected during the supplementation and wash-out periods (data not 
shown). 
 
DISCUSSION 
This study shows that compared to young adults, healthy, free-living elderly 
from our region of Québec have a somewhat higher response of plasma DHA to a 
short-term daily fish oil supplement. This result contradicts our initial hypothesis that 
the plasma response to a fish oil supplement would be significantly dampened in the 
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healthy elderly. Higher baseline plasma EPA in our elderly group (Table 1) confirms 
observations reported previously for plasma EPA (8,9) and red cell 3 PUFA (10,11). 
In 30 year old women, plasma EPA tends to rise more quickly than DHA during short 
term supplementation with fish oil and fall more quickly after the supplementation 
period (12). 
Despite raising DHA intake by 5-10 fold compared to average intake in 
Quebec (6) and approximately doubling plasma total DHA during the 
supplementation period, in neither group did plasma free DHA rise significantly during 
the supplementation period nor fall during the wash-out (whether expressed as % or 
as mg/dL). The higher concentration of free plasma DHA in our elderly subjects was 
clearly a function of a larger plasma free fatty acid pool and not due to higher % DHA 
in plasma free fatty acids. No change in % DHA in plasma free fatty acids has 
previously been reported during a 3 wk supplementation with 750 mg/d of DHA but 
no EPA (13). However, in that study, plasma free DHA did rise significantly after the 
6th week of supplementation or when a 1500 mg daily dose of DHA was given. We 
focused on plasma free DHA because of its purported role as a precursor to brain 
DHA (5). Given the emerging though still controversial link between low DHA status 
and increased risk of cognitive decline in the elderly (3), it was therefore not 
anticipated that the pool of plasma free DHA would be higher in the elderly than in 
our young subjects. If, as proposed by Lagarde’s group, a lysophosphatidylcholine 
form of DHA is the carrier of DHA to the brain (14), then the larger pool of plasma 
free DHA in the elderly would have no direct bearing on their susceptibility to 
cognitive decline.   
In all plasma lipid classes we evaluated, ARA was statistically unaffected by 
an intake of about 1000 mg/d of 3 fatty acids, given mostly as EPA and DHA. 
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Higher baseline ARA in our elderly group contrasts somewhat with the results of 
Rees et al (9) but their elderly group was 15 y younger than ours. Rees et al (9) also 
used a higher dose of EPA and DHA and for a longer period but otherwise both our 
studies agree that raising EPA and DHA intake by up to 10 fold does not seem to 
significantly affect plasma ARA. 
Incomplete compliance is one potential confounder that was not a factor in the 
results of the present study. Our stable isotope-based method was relatively non-
invasive and well tolerated. It was a good independent measure of compliance but 
because of cost, labor-intensiveness and the need for specialized equipment to 
analyze 13C in breath CO2, it perhaps not widely applicable.  
We conclude that during short-term supplementation with fish oil capsules, 
healthy aging is associated with significantly higher DHA incorporation into plasma 
lipids. This result contributes to the emerging literature suggesting that subtle but 
potentially important changes in 3 PUFA metabolism occur during healthy aging. 
The possible relevance of these aging-related changes in 3 PUFA metabolism to 
risk of chronic disease, particularly cognitive decline, remains to be established.  
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Figure legends 
 
Figure 1   
Docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and arachidonic 
acid (ARA) in plasma total lipids (%) during 3 weeks supplementation and 2 weeks 
follow up in 9 young and 10 elderly subjects. Black squares - young adults, White 
squares – elderly adults: mean ± SD, * p<0.05. 
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Table 1 
 
 
Baseline characteristics of the two groups. 
 
 
 
 
Mean ± SD 
 
*p<0,05, Mann-Whitney 
 
  **Plasma total lipids 
Group 
Young 
(n=9) 
Elderly 
(n=10) 
Age 24 ± 2 74 ± 4 * 
Male/Female   5/4 5/5 
Weight (kg)   71.1 ± 18.1 75.0 ± 13.4 
Body Mass Index (kg/m2) 24.5 ± 4.1   28.0 ± 4.3 
Free Fatty Acids (mmol/L)   0.48 ± 0.21 0.62 ± 0.24 
Phospholipids (mmol/L)   0.72 ± 0.21 0.84 ± 0.17 
Triglycerides (mmol/L)   1.0 ± 0.4 1.3 ± 0.4 
Cholesterol (mmol/L)   4.4 ± 0.6  5.5 ± 0.9 * 
Fatty acids** (%)   
Sum Saturates 28.9 ± 2.5    29.5 ± 2.5 
Sum Monounsaturates 24.7 ± 3.8  27.6 ± 2.6 * 
Linoleate   34.3 ± 3.1  28.8 ± 3.2 * 
Arachidonate   6.6 ± 0.9    7.5 ± 1.0 * 
α-Linolenate   1.0 ± 0.5  0.8 ± 0.3 
Eicosapentaenoate   0.6 ± 0.3    1.0 ± 0.3 * 
Docosapentaenoate   0.4 ± 0.2  0.5 ± 0.1 
Docosahexaenoate   1.5 ± 0.5  1.6 ± 0.6 
